Amneal Pharmaceuticals, Inc.
NASDAQ:AMRXDrug Manufacturers - Specialty & Generic
-$0.15 today
- Market cap
- $7.62B
- Beta
- 1.32
- P/E (TTM)
- 43.4
- EPS (TTM)
- $0.37
Volume 1.91M
Average 1.75M
AMRX Total Liabilities
Everything the company owes to creditors and other parties.
Amneal Pharmaceuticals, Inc.NASDAQ: AMRX
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities rises 5.5% from a year ago
Total liabilities stood at $3.66B at the end of Q2 FY2026, up 5.5% from a year earlier and up 2.0% from the prior quarter. Over 3 fiscal years it compounded at +0.8% a year.
Context
- Total liabilities amounted to 96.9% of total assets at the end of Q2 FY2026, down 4.5 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +5.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 3.67B USD
- Year-over-year change
- +3.6%
- 4-year CAGR
- +0.7%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.67B | +3.6% |
| FY2024 | 2024-12-31 | 3.55B | +3.9% |
| FY2023 | 2023-12-31 | 3.41B | -5.0% |
| FY2022 | 2022-12-31 | 3.59B | +0.5% |
| FY2021 | 2021-12-31 | 3.57B | — |
Total Liabilities vs competitors
How AMRX compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +5.5% is the 2nd highest of 11, against a peer median of -4.6%.
- Total liabilities amounts to 96.9% of total assets for AMRX, versus a peer median of 63.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | ₹185.92B INR | +3.3% | +29.0% | 32.2% | |
| Jun 2026 | $32.1B USD | -3.6% | -2.5% | 80.5% | |
| Jun 2026 | $25.6B USD | -5.6% | +0.7% | 103.2% | |
| Jun 2026 | $20.78B USD | -9.0% | -8.1% | 59.3% | |
| Jun 2026 | $5.09B USD | -9.4% | -3.2% | 66.9% | |
| Jun 2026 | $3.66B USD | +5.5% | +0.8% | 96.9% | |
INDVIndivior Pharmaceuticals Inc | Jun 2026 | $1.44B USD | -15.7% | -9.0% | 116.9% |
| Mar 2026 | $874.77M USD | -0.0% | +57.9% | 53.1% | |
| Mar 2026 | $859.67M USD | +1.3% | +28.7% | 60.5% | |
| Mar 2026 | $797.3M USD | -8.7% | -23.5% | 60.4% | |
| Mar 2026 | $49.69M USD | +19.5% | -2.8% | 70.0% | |
| Peer median (excluding AMRX) | — | -4.6% | -2.7% | 63.7% | |
Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 247.79M | 25.98M | 91.54M | 110.55M | 310.87M |
| Short-term Investments | 0 | 1.82M | 2.2M | 1.87M | 0 |
| Net Receivables | 694.74M | 741.79M | 645.66M | 775.73M | 939.87M |
| Inventory | 489.39M | 530.74M | 581.38M | 612.45M | 606.3M |
| Other Current Assets | 41.95M | 64.37M | 7.57M | 40.7M | 4.44M |
| Total Current Assets | 1.52B | 1.41B | 1.38B | 1.59B | 1.91B |
| Property, Plant & Equipment (Net) | 639M | 589.36M | 550.14M | 523.69M | 550.33M |
| Goodwill | 593.02M | 598.85M | 598.63M | 597.44M | 595.47M |
| Intangible Assets | 1.17B | 1.1B | 890.42M | 732.38M | 563.5M |
| Long-term Investments | 0 | 85.59M | 37.09M | 35.92M | 7.82M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 20.61M | 17.63M | 18.43M | 24.21M | 49.98M |
| Total Non-current Assets | 2.42B | 2.39B | 2.09B | 1.91B | 1.77B |
| Total Assets | 3.94B | 3.8B | 3.47B | 3.5B | 3.68B |
| Account Payables | 131.08M | 166.84M | 143.57M | 259.84M | 254.67M |
| Short-term Debt | 30.61M | 89.96M | 213.13M | 324.21M | 21.58M |
| Tax Payables | 2.52M | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 398.41M | 0 | 0 |
| Other Current Liabilities | 120.1M | 263.11M | 3.91M | 222.36M | 525.5M |
| Total Current Liabilities | 677.24M | 752.8M | 846.6M | 1.13B | 881.63M |
| Long-term Debt | 2.72B | 2.63B | 2.43B | 2.16B | 2.61B |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 65.43M | 97.12M | 41.77M | 163.33M | 75.79M |
| Total Non-current Liabilities | 2.9B | 2.84B | 2.56B | 2.42B | 2.79B |
| Total Liabilities | 3.57B | 3.59B | 3.41B | 3.55B | 3.67B |
| Common Stock | 3.01M | 3.04M | 3.07M | 3.1M | 3.15M |
| Retained Earnings | (276.2M) | (406.18M) | (490.18M) | (607.06M) | (535.01M) |
| Accumulated OCI | (24.83M) | 9.94M | (32.35M) | (65.51M) | (110.73M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 6.63M | (89.49M) | 41.52M | 64.73M | 76.76M |
| Total Equity | 366.97M | 208.93M | 61.3M | (44.54M) | 5.96M |
| Total Debt | 2.88B | 2.85B | 2.75B | 2.59B | 2.74B |
| Net Debt | 2.63B | 2.82B | 2.66B | 2.48B | 2.43B |
Amneal Pharmaceuticals, Inc.
NASDAQ:AMRX
Intrinsic Alpha fair value
Locked
Current Price
$21.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.